Business
Ensysce Biosciences Announces Engagement of Alacrita Consulting
Engagement to aid expansion of the use of TAAP and MPAR® as well as the rapid development and commercialization of Ensysce's next generation opioidsSAN DIEGO,
About this update from Ensysce Biosciences, Inc.
[{"type":"text","content":"Engagement to aid expansion of the use of TAAP and MPAR® as well as the rapid development and commercialization of Ensysce's next generation opioidsSAN DIEGO, CA / ACCESSWIRE / July 26, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced it has engaged Alacrita Consulting (\"Alacrita\"), a pharma and biotech consulting firm with extensive subject-matter expertise for the purpose of exploring partnering and licensing opportunities for its TAPP and MPAR® platforms and products.Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce commented, \"We are pleased to be working with Alacrita and its team of highly experienced experts to explore opportunities to aid our growth and development.\" Dr. Kirkpatrick added, \"Our goal is to rapidly develop both PF614 and PF614-MPAR, as well as expand the use of our TAAP and MPAR® technologies, and we believe Alacrita's team is the perfect group to aid us in achieving this goal.\"About AlacritaFounded in 2009, Alacrita is an expertise-based consulting firm serving biotech and pharma companies, academic institutions and healthcare investors, across a range of disciplines, therapeutic areas and technologies. Its core team leverages a consulting network of 250+ functional specialists, all with at least 20 years of pharmaceutical industry experience, allowing it to offer a versatile combination of depth and breadth in expertise that is unrivaled in the industry and that can be precisely tailored to the needs of each client. The firm provides consulting support on a range of R&D and business issues.About Ensysce BiosciencesEnsysce Biosciences is a clinical-stage company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAPTM) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is in the process of developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug composit...